Today is the 5th annual Bell Let’s Talk Day, with Clara Hughes leading the campaign inviting all Canadians to talk, text and tweet and share on Facebook about mental health and help build a Canada free of the stigma of mental illness.
In a press release yesterday, Clara, Canada’s 6-time Olympic medalist and national Bell Let’s Talk ambassador since the launch of the initiative in 2010, said: “I’m really looking forward to kicking off the national conversation about mental health with Bell Let’s Talk Day 2015! Join us in the fight against the stigma that makes most who struggle with mental illness reluctant to ask for help.”
Mental illness is associated with other diseases, one of which is a type of arthritis called fibromyalgia. Fibromyalgia is characterized primarily by chronic widespread pain (CWP) in the muscles, ligaments and tendons, and a heightened sensitivity to touch resulting in pain that can last for months.
Arthritis Research Canada and its Scientific Director, Dr. John Esdaile, have received the 2014 Canadian Institutes of Health Research (CIHR) Partnership Award for developing, in collaboration with Arthritis Consumer Experts (ACE) and Shoppers Drug Mart/Pharmaprix, an innovative screening program to help Canadians better prevent and manage arthritis.
To learn about this partnership, please visit the associated links below:
CIHR’s news release
Ministerial Announcement – Health Minister Rona Ambrose Launches Innovative Arthritis Screening Program at Shoppers Drug Mart
Shoppers Drug Mart
ARTHRITIS CONSUMER EXPERTS ASKS CANADIANS: HOW DOES YOUR PROVINCE MEASURE UP?
ACE’s Arthritis Medications Report Card helps Canadians evaluate reimbursement access to arthritis medications
(Vancouver, BC) — In its eighth annual JointHealth™ Arthritis Medications Report Card, Arthritis Consumer Experts (ACE) reports that, depending on where they live, Canadians living with an autoimmune arthritis may have fewer treatment options or have to “jump through more hoops” to qualify for reimbursement for the medication prescribed for them by their rheumatologist.
“ACE continues to fight for the rights of people with arthritis, which includes our leadership on timely and equitable reimbursement access to arthritis medications on public and private drug formularies. Studies have found that increases in medication treatment costs for rheumatoid arthritis over the last decade are associated with lower hospitalization rates, better functional status and a lower incidence of work disability,” said Cheryl Koehn, Founder and President of Arthritis Consumer Experts.
A holiday message from Cheryl Koehn of Arthritis Consumer Experts
Dear ACE members, subscribers and on-line visitors,
This year marks the 17th holiday season Arthritis Consumer Experts (ACE) is sharing with our members and supporters across Canada. It is a time to give thanks for everything that makes this time of year so magical — spending time with friends and family and spreading tidings of health and wellness, especially to people living with arthritis.
This time of year also reminds us we all have a responsibility to ourselves and to each other to make a difference that is real and lasting. As Canada’s leading provider of evidence-based arthritis consumer information and education delivery and advocacy work, ACE strived to make a difference in 2014 on behalf of the more than 4.6 million Canadians living with the disease. Our organization served people living with all forms of arthritis by continuing to advocate on health and policy issues, such as the emergence of new treatment options and reimbursement access to medications, to patients, healthcare professionals, media and public and private formularies through ACE’s JointHealth™ family of programs and the Arthritis Broadcast Network.
In this season of generosity, ACE encourages you to reach out to those who need help the most.
In this season of reflection, let’s also make sure that our incredibly brave children, employees, parents, and seniors living with one of the more than 100 types of arthritis know how much we admire their will to live their lives fully and contribute to their community.
In this season of hope, let us come together and commit that in 2015 we do everything we can to build on the progress we’ve made this past year and ensure there is enhanced awareness and excellence in standards of care for people living with arthritis all across Canada.
On behalf of my ACE team members and our Scientific, Medical and Consumer Advisory Board, I want to wish you a joyful holiday season!
Person with rheumatoid arthritis and President of Arthritis Consumer Experts
The JointHealth™ Arthritis Medications Report Card: How Does Your Province Measure Up?
While there are no cures for arthritis, scientific advances and improved treatments, along with a better understanding of combination medication therapy, are allowing people with arthritis to live healthier, more productive lives. In the last year, advances in arthritis treatment include the expansion of two new classes of medications used to treat autoimmune forms of arthritis. This year’s JointHealth™ Arthritis Medications Report Card reflects this change and covers three medication categories – biologic response modifiers, subsequent entry biologics, and targeted small molecule medications – increasing the number of individual arthritis medications evaluated in the Report Card to 13.
What has ACE done for you lately? Here’s what we’ve been up to in November!
In this issue of “What has ACE done for you lately” – a monthly roundup of what we have accomplished and what we are currently working on – we highlight our campaigns in the workplace, healthcare, arthritis community and research.
ACE at the American College of Rheumatology Meeting
Arthritis Consumer Experts (ACE) attended the American College of Rheumatology (ACR) Annual Meeting in Boston in November. ACE networked with rheumatologists, researchers, healthcare professionals, patient organization and patients living with arthritis to understand the future of arthritis treatment and the promises they may hold for people living with the disease. Continue reading